High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma

Fumiaki Isohashi, Yasuo Yoshioka, Masahiko Koizumi, Koji Konishi, Iori Sumida, Yutaka Takahashi, Toshiyuki Ogata, Ken ichirou Morishige, Takayuki Enomoto, Yoshifumi Kawaguchi, Tadayuki Kotsuma, Kana Adachi, Shoichi Fukuda, Yuichi Akino, Takehiro Inoue

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Purpose: The aim of the study was to evaluate the results of high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with advanced cervical carcinoma in which intracavitary radiation therapy may result in a suboptimal dose distribution. Methods and Materials: Between 1995 and 2005, 25 patients of median age 64 years were treated with external beam radiation therapy and HDR-ISBT. The International Federation of Gynecology and Obstetrics stages of the patients were I (4%), II (16%), III (68%), and IVA (12%). Whole pelvic irradiation of 30 Gy/15 fractions was followed by HDR-ISBT of 30 Gy/5 fractions/3 days. Subsequently, additional pelvic external beam radiation therapy of 20 Gy/10 fractions was delivered with a midline block. The median followup period was 55 months. Results: The actuarial 5-year progression-free survival and overall survival rates for all cases were 42% and 54%, respectively. For the 17 patients with a Stage III tumor, the 5-year local control and overall survival rates were 73% and 51%, respectively. Two patients (8%) developed late toxicities of Grade 3. Conclusions: A high rate of pelvic control and survival with acceptable level of late toxicities were obtained for patients with advanced cervical carcinoma treated with HDR-ISBT.

Original languageEnglish (US)
Pages (from-to)234-239
Number of pages6
JournalBrachytherapy
Volume8
Issue number2
DOIs
StatePublished - Apr 2009

Keywords

  • Brachytherapy
  • Cervical carcinoma
  • High dose rate
  • Interstitial
  • Previously untreated

Fingerprint Dive into the research topics of 'High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma'. Together they form a unique fingerprint.

Cite this